Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 28Rectal Neoplasms 6Colonic Neoplasms 6Stomach Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasm Metastasis 3Neutropenia 2Neoplasms 2Colorectal Cancer Metastatic 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Advanced Solid Tumors 2mCRC 1Spinocerebellar Degenerations 1Solid Tumor Cancer 1Sarcoma, Ewing 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Microsatellite-stable Colorectal Cancer 1Metastatic Gastric Adenocarcinoma 1Lung Neoplasms 1High-grade Extra Pulmonary Neuroendocrine Cancer 1HER2 IHC3+ Advanced Colorectal Cancer 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Gastric and Gastroesophageal Junction Adenocarcinoma 1Gallbladder Neoplasms 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1

Interventions

pembrolizumab 91Carboplatin 79Specimen Handling 76Magnetic Resonance Spectroscopy 64Pemetrexed 60Cisplatin 49durvalumab 44Paclitaxel 38Nivolumab 34atezolizumab 32Radiotherapy 30Radiosurgery 30osimertinib 29Blood Specimen Collection 27Biopsy 26Gemcitabine 24Docetaxel 24Immunoglobulin G 23Standard of Care 22Disulfides 22Etoposide 21Drug Therapy 21Taxes 18Practice Guidelines as Topic 18Radiation 17Educational Status 16130-nm albumin-bound paclitaxel 15X-Rays 14Surveys and Questionnaires 14Bevacizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × trifluridine tipiracil drug combination × 1 year × Clear all
NCT04701476 2026-04-16

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

Teclison Ltd.

Phase 2 Recruiting
110 enrolled
GastrointestinalThoracic

Lung Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡